Product Description
CI-1040 (PD184352) is an orally active, highly specific, small-molecule inhibitor of one of the key components of this pathway (MEK1/MEK2), and thereby effectively blocks the phosphorylation of ERK and continued signal transduction through this pathway. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/14613031/)
Mechanisms of Action: N/A
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 2: Breast Cancer|Non-Small-Cell Lung Cancer|Pancreatic Cancer|Colorectal Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
CDR0000069279 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Pancreatic Cancer|Breast Cancer|Colorectal Cancer |
2003-11-01 |
|
NCT00034827 | P2 |
Completed |
Non-Small-Cell Lung Cancer|Pancreatic Cancer|Breast Cancer|Colorectal Cancer |
None |